BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.
BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech’s experimental COVID-19 vaccine in China.
The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future approval in China, the two companies said in a statement.
- Covid-19: Ahmedabad Corporation makes vaccine mandatory for city buses, tourist places, libraries, check details
- Dr Gagandeep Kang on the road ahead with COVID-19, booster shots & on inoculating approach for children
- Covid vaccines donated by India earlier this year for UN peacekeepers exhausted: UN spokesperson
BioNTech is also working with U.S. pharma giant Pfizer on the vaccine and the partners said last week they were hoping to win approval in the United States and Europe this year after trial results showed the compound had a 95% efficacy rate and caused no serious side effects.